Acceleron Pharma (NASDAQ:XLRN) SVP John D. Quisel sold 1,204 shares of the business’s stock in a transaction dated Tuesday, April 3rd. The stock was sold at an average price of $38.40, for a total transaction of $46,233.60. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.
XLRN stock opened at $36.47 on Friday. Acceleron Pharma has a fifty-two week low of $24.37 and a fifty-two week high of $46.93. The company has a market cap of $1,741.82, a P/E ratio of -13.61 and a beta of 1.43.
Acceleron Pharma (NASDAQ:XLRN) last released its earnings results on Tuesday, February 27th. The biopharmaceutical company reported ($0.62) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.60) by ($0.02). Acceleron Pharma had a negative return on equity of 38.71% and a negative net margin of 804.49%. The firm had revenue of $3.71 million for the quarter, compared to analysts’ expectations of $3.39 million. analysts predict that Acceleron Pharma will post -2.5 EPS for the current fiscal year.
A number of analysts have issued reports on the stock. Credit Suisse Group reiterated an “outperform” rating and set a $55.00 price target on shares of Acceleron Pharma in a research note on Thursday, January 18th. HC Wainwright reiterated a “buy” rating and set a $62.00 price target on shares of Acceleron Pharma in a research note on Monday, December 11th. Piper Jaffray boosted their price target on shares of Acceleron Pharma to $53.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 28th. BidaskClub upgraded shares of Acceleron Pharma from a “hold” rating to a “buy” rating in a research note on Thursday, February 15th. Finally, ValuEngine upgraded shares of Acceleron Pharma from a “hold” rating to a “buy” rating in a research note on Monday, April 2nd. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and twelve have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $47.06.
Several hedge funds have recently added to or reduced their stakes in the stock. Public Employees Retirement Association of Colorado acquired a new position in Acceleron Pharma in the fourth quarter valued at approximately $138,000. Amalgamated Bank acquired a new position in Acceleron Pharma in the fourth quarter valued at approximately $217,000. Xact Kapitalforvaltning AB acquired a new position in Acceleron Pharma in the fourth quarter valued at approximately $217,000. Oppenheimer & Co. Inc. acquired a new position in Acceleron Pharma in the third quarter valued at approximately $225,000. Finally, Trexquant Investment LP acquired a new position in Acceleron Pharma in the third quarter valued at approximately $266,000. Hedge funds and other institutional investors own 88.23% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Acceleron Pharma (XLRN) SVP Sells $46,233.60 in Stock” was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece of content on another site, it was illegally stolen and reposted in violation of United States & international trademark & copyright legislation. The original version of this piece of content can be read at https://www.dispatchtribunal.com/2018/04/07/acceleron-pharma-xlrn-svp-sells-46233-60-in-stock.html.
About Acceleron Pharma
Acceleron Pharma Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. Its therapeutic candidates include luspatercept, which is in Phase III clinical trials for the treatment of myelodysplastic syndromes and beta-thalassemia; Phase II clinical trials for the treatment of patients with transfusion-dependent beta-thalassemia and myelofibrosis.
Receive News & Ratings for Acceleron Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acceleron Pharma and related companies with MarketBeat.com's FREE daily email newsletter.